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Platelets are small anucleated cells present only in mammals. Platelets mediate
intravascular hemostatic balance, prevent interstitial bleeding, and have a major role
in thrombosis. Activation of platelet purinergic receptors is instrumental in initiation
of hemostasis and formation of the hemostatic plug, although this activation process
becomes problematic in pathological settings of thrombosis. This review briefly outlines
the roles and function of currently known platelet purinergic receptors (P1 and P2) in
the setting of hemostasis and thrombosis. Additionally, we discuss recent novel studies
on purinergic receptor distribution according to heterogeneous platelet size, and the
possible implication of this distribution on hemostatic function.
Keywords: platelets, purinergic receptors, ATP, ADP, adenosine
INTRODUCTION
Adenine nucleosides and nucleotides accumulate in the circulation under various pathological
conditions and can initiate and mediate the response to cell damage, hypoxia, and inflammation
(Koupenova and Ravid, 2013). Additionally, adenosine diphosphate (ADP) and adenosine
triphosphate (ATP) are released from dense-granules during platelet activation and propagate
platelet–platelet interactions, ultimately leading to three-dimensional plug formation that seals
endothelial damage (McNicol and Israels, 1999; Koupenova and Ravid, 2013; Koupenova et al.,
2017). Adenosine, in turn, is not known to be present in platelets but is generated in the
extracellular space from ATP and ADP by two ectonucleotidases, CD39 (ENTPD1) and CD73
(NT5E) (reviewed in Koupenova and Ravid, 2013), that are present on endothelial and platelet
surfaces (Koziak et al., 1999; Castilhos et al., 2016).
Two major classes of receptors mediate the physiological effect of adenosine and adenosine
phosphates. These are the P1 and P2 purinergic receptors, classified based on their preference for
adenosine (P1) or adenosine phosphates (P2). The P1 purinergic receptors include four G-protein-
coupled receptors, two that activate adenylate cyclase [Adora2A (A2aAR) and Adora2b (A2bAR)]
and generate cyclic AMP (cAMP), and two that inhibit adenylate cyclase [AdoraA1 (A1AR)
and AdoraA3 (A3AR)] and decrease cAMP. The P2 purinergic receptor group is subdivided
further into two groups that, in platelets, are represented by receptors activated by ATP (P2X1)
and receptors activated by ADP (P2Y1 and P2Y12). P2Y1 and P2Y12 are G-protein-coupled
receptors, while P2X1 is a ligand-gated ion channel receptor (Jacobson et al., 2006; Cattaneo, 2007).
Adenosine and adenosine phosphates play a central role in regulating platelet behavior during
hemostasis and thrombosis, as ADP induces platelet activation, while adenosine, for the most
Frontiers in Pharmacology | www.frontiersin.org 1 January 2018 | Volume 9 | Article 37
fphar-09-00037 January 27, 2018 Time: 15:15 # 2
Koupenova and Ravid Platelet Purinergic Receptors and Their Heterogeneity
part, inhibits it. ATP, in turn, can initiate platelet activation
through the P2X1 receptor and inhibit ADP-mediated activation
when acting as an antagonist on the P2Y receptors (Cattaneo,
2007). The potential explanation as to why platelets have both
ATP and ADP receptors is that all of the purinergic receptors are
necessary for establishing a balanced regulation of hemostasis or
thrombus formation, depending on the intensity of vessel injury.
Nucleotides released from damaged cells may occupy platelet
P2 receptors and initiate shape change (via P2X receptors) and
aggregation (via P2Y12 and P2Y1 receptor). The level of ADP-
mediated P2Y12 or P2Y1 receptor activation can be controlled by
ATP. Conversion of ATP and ADP (by CD39/CD73) to adenosine
provides a second level of regulation that controls propagation
of the hemostatic plaque by inhibiting activation through the
A2 ARs. Deeper damage of the vessel leads to an increase
in platelet aggregation response (collagen- or tissue factor-
mediated) in order to prevent leakage into the interstitial tissue.
This simplified explanation, however, is complicated by the fact
that platelets are a heterogeneous population (as discussed in the
last section of this review) and there is differential expression
of distinct purinergic receptors based on size and function. In
this review, we will focus on the role of purinergic receptors
in platelet function and their distribution according to platelet
heterogeneity.
PURINERGIC RECEPTORS IN
HEMOSTASIS
Recent in vivo studies have further clarified the complex
interactions and agonist distribution in the formation of three-
dimensional platelet arrangement during hemostasis. According
to this newly elucidated model, the hemostatic plug is composed
of a core and an outer shell through which platelets are
differentially activated. The stringent plug architecture consists
of a platelet activation gradient with the most activated platelets
in the core of the clot, surrounded by less activated platelets in the
outer shell region. Fibrin deposition is localized distinctly at the
base of the core in the extravascular space before hemostasis is
achieved (Stalker et al., 2013; Tomaiuolo et al., 2017). The inner
core of the hemostatic plug is packed tightly with degranulated
platelets that are P-selectin positive. The outer shell is composed
of loosely packed platelets that do not express P-selectin, and
there is little to no fibrin present.
Although stable, the outer shell is porous and permeable
to plasma solutes. Consistent with the platelet activation
distribution gradient, there is a distinct distribution of platelet
agonists throughout the hemostatic plug. The core of the
plug contains a high concentration of thrombin (factor IIa)
and, as the plug becomes more porous, a gradient of ADP
and thromboxane A2 (TxA2) develops (Stalker et al., 2013;
Tomaiuolo et al., 2017). The porous outer shell of the thrombus
allows for recruitment of leukocytes necessary for injury repair
or pathogen elimination. An increase in thrombin leads to
PAR4 cleavage, consequently leading to leukocyte recruitment
and migration to the damaged endothelium (Kaplan et al.,
2015). Leukocyte recruitment, in turn, is limited by binding of
thrombin to platelet GP1bα that can reduce platelet activation.
Additionally, fibrin deposition in the thrombus physically
inhibits leukocyte migration (Kaplan et al., 2015). The distinct
distribution of P-selectin expressing platelets in the core vs.
P-selectin-negative platelets in the shell suggests a possibility
for a specific distribution of different platelet subpopulations
throughout the hemostatic plug, according to their function in
the interaction with either damaged endothelium or circulating
leukocytes.
PLATELETS AND P2 RECEPTORS
ATP Receptors in Platelets
The P2X1 receptor is a ligand-gated ion channel receptor
(Sun et al., 1998) that is activated by ATP and inhibited
by ADP. Binding of ATP to the P2X1 receptor leads to
calcium influx into platelets (Rolf et al., 2001; Mahaut-Smith,
2012) which consequently results in a transient change of
platelet shape, platelet degranulation, pseudopodia formation,
and platelet activation (Rolf et al., 2001; Toth-Zsamboki et al.,
2003; Mahaut-Smith, 2012). P2X1 receptor activation by ATP
alone does not mediate platelet aggregation; however, it can
amplify ADP-mediated aggregation through the platelet-P2Y1
receptor (Jones et al., 2014). Furthermore, during early stages
of vessel damage, in the presence of a low concentration of
collagen, ATP contributes to increased aggregation through the
P2X1 receptor (Oury et al., 2001). Similarly, P2X1 receptors
can amplify thrombin-mediated platelet aggregation through
protease-activated receptor 1 (PAR1) at low levels of thrombin
(Erhardt et al., 2006). Importantly, in the presence of collagen or
pathogenic stimuli, endothelial inhibitors (such as prostacyclins)
are unable to completely inhibit calcium-mediated platelet
aggregation partially due to activation of P2X1 receptor by ATP
(Fung et al., 2012).
Intracellularly, P2X1 activation leads to MAPK/ERK2
pathway signaling that contributes to myosin light chain (MLC)
phosphorylation and propagation of collagen-mediated platelet
secretion (Toth-Zsamboki et al., 2003). During high shear
stress, ATP-activated P2X1 also contributes to platelet-induced
aggregation by MLC-mediated cytoskeletal rearrangements
(Oury et al., 2004). P2X1 activation by ATP can also contribute to
platelet secretion of TxA2 and enhance TxA2-mediated platelet
aggregation (Huang et al., 2014). Additionally, in cases of a
co-stimulatory role with P2Y1 signaling, P2X1 increases the
influx of calcium and amplifies the consequent calcium signaling
through P2Y1 and other Gαq-coupled platelet receptors (Jones
et al., 2014). Therefore, at sites of vascular injury, intensity of the
platelet response can be regulated by the availability of various
forms of adenosine phosphates.
Murine platelets lacking the P2X1 receptor exhibit decreased
collagen-induced aggregation and adhesion (Hechler et al.,
2003a). Furthermore, these platelets show diminished thrombus
growth on collagen-coated slides, particularly at higher shear
stress (Hechler et al., 2003a). Overall, P2X1 activation seems to
be important at high shear stress and low agonist concentration,
suggesting that ATP contributes to platelet aggregation at the
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initial stages of platelet attachment to damaged endothelium,
particularly in the arteries.
ADP Receptors in Platelets
P2Y12 and P2Y1 receptors are G-protein-coupled receptors
activated by ADP and inhibited by ATP. With respect to
adenine nucleotide-mediated aggregation in platelets, the ADP-
activated P2Y12 receptor is the most important receptor. P2Y12
was first discovered in 2001 (Hollopeter et al., 2001), and
it can couple to the Gαi subunit leading to the inhibition
of adenylyl cyclase that mediates the conversion of ATP to
cAMP (Hollopeter et al., 2001; Cattaneo, 2007; Hechler and
Gachet, 2011). Consequently, the overall levels of cAMP can be
decreased which may lead to an increase in platelet activation
state. One of the mechanisms by which cAMP reduces platelet
aggregation involves activation of protein kinase A (PKA) which
leads to the phosphorylation and inhibition of inositol 1,4,5-
triphosphate (IP3) receptor-mediated increase of calcium from
the dense tubular system; reduced levels of cAMP have the
opposite effect on IP3 and consequently increase intracellular
calcium (Quinton and Dean, 1992; Tertyshnikova and Fein,
1998). In addition to coupling through Gαi and inhibition of
adenylyl cyclase, ADP-mediated activation of P2Y12 receptors
leads to activation of PI-3 kinase (PI-3K) through Gβγ (Shankar
et al., 2004). It is now understood that the P2Y12 receptor
contributes to the ADP-mediated calcium response (by P2Y1)
in platelets by activating PI-3K, in addition to simultaneously
inhibiting adenylyl cyclase, i.e., by reducing cAMP levels (Hardy
et al., 2004). Importantly, ADP activation through Gαi-coupled
P2Y12 receptors and the consequent RAP1 activation is critical
for GPIIb/IIIa integrin-mediated platelet aggregation (Larson
et al., 2003; Stefanini and Bergmeier, 2017). The P2Y12, but
not P2Y1 receptor is required for sustained activation of RAP1
(Ras-related protein 1). P2Y12 is necessary for the formation
of a shear-resistant hemostatic plug which is mediated by locally
secreted ADP from platelets (Larson et al., 2003; Stolla et al.,
2011b; Stefanini and Bergmeier, 2017). RAP1 activation is also
dependent on guanine exchange factor (GEF), proteins RapGEF
and RAS guanyl releasing protein 2 (RASGRP2), that are
regulated by intracellular calcium signaling and by inhibition
from the GTP-ase activating protein Ras GTPase-activating
protein 3 (RASA3) (Stolla et al., 2011a; Stefanini and Bergmeier,
2017). ADP-activated P2Y1 receptor, on the other hand, does
not affect cAMP levels (Fabre et al., 1999), couples to the Gαq
subunit leading to the activation of phospholipase C (PLC)
(Cattaneo, 2007; Hechler and Gachet, 2011). In platelets, PLC
activation leads to a cascade of molecular signaling events that
result in increased levels of cytosolic calcium, particularly from
the dense tubular system. Interestingly, the P2Y1 receptor is
able to activate Src kinase and consequently establish negative
regulation over P2Y12 signaling through PI-3K (Hardy et al.,
2004). This suggests that for ADP-mediated calcium signaling
in platelets, P2Y12 and P2Y1 receptors cross-communicate to
establish a controlled response to vascular damage; the P2Y12
receptor contributes to the absolutely required P2Y1-mediated
calcium response by activating PI-3K and reducing cAMP levels,
while the P2Y1 receptor inhibits PI-3K by coupling with Src
kinase (Hardy et al., 2004). Thus, now it is understood that, in
addition to ADP activation of platelets through two different
molecular signaling mechanisms in which platelet activation by
P2Y1 leads to rapid shape change and reversible aggregation
while P2Y12 activation induces sustained platelet aggregation but
without a shape change (Cattaneo, 2007; Hechler and Gachet,
2011), there is also a synergy between these receptors at the
level of calcium signaling (Hardy et al., 2004). Importantly, other
platelet G-protein-coupled receptor signaling through Gαq and
contribution to the overall calcium pool can further synergize
with ADP receptors and affect platelet function. Detailed reviews
of platelet P2 signaling and synergy at calcium regulation can be
found elsewhere (Dorsam and Kunapuli, 2004; Cattaneo, 2007;
Varga-Szabo et al., 2009; Hechler and Gachet, 2011; Stefanini and
Bergmeier, 2017).
It is important to mention that the role of ADP secreted
from platelet dense-granules is to amplify the aggregation signal
induced by other strong platelet agonists (such as TxA2), assuring
stable platelet aggregation. Conversely, coordinated signaling
involving activation of the P2Y12 and P2Y1 ADP receptors and
integrin GPIIb/IIIa can mediate TxA2 generation (Jin et al.,
2002). This multifactorial ADP receptors–TxA2 axis in platelets
is important for thrombus growth and stabilization. Interestingly,
patients deficient only in P2Y12 receptors have unaffected TxA2
production (Cattaneo et al., 1992, 2000), suggesting an important
requirement of the two ADP receptors for proper hemostasis.
Studies utilizing murine platelets deficient in P2Y1 receptor
showed that these platelets lack shape change and are prone to
decreased aggregation in response to high concentrations of ADP
(Fabre et al., 1999; Leon et al., 1999). However, P2Y1-deficient
platelets had strongly impaired aggregation at low concentrations
of ADP or collagen (Leon et al., 1999), suggesting that the
P2Y1 receptor contributes to the overall ADP-mediated platelet
aggregation and responses to other agonists. On the other hand,
platelet overexpression of the P2Y1 receptor induces platelet
hyperactivity (Hechler et al., 2003b). Bleeding time of mice
deficient in this receptor is increased and they are protected
from collagen- or ADP-induced thromboembolism (Fabre et al.,
1999; Leon et al., 1999), suggesting that P2Y1 mediates ADP–
platelet aggregation effects in vivo. Studies utilizing a murine
model deficient in P2Y12 (Andre et al., 2003) in the context of the
mesenteric artery injury model, support the observation that this
receptor mediates platelet adhesion and activation, in addition to
mediating the growth and stability of the thrombus. Consistently,
in vivo antagonism of the P2Y12 receptor in rabbits reduces
the size of the initial thrombus in injured mesenteric arterioles.
However, in this study utilizing P2Y12 antagonists, AR-C69931
MX or clopidogrel (vs. genetic elimination), the stability of the
thrombus was not affected by P2Y12 and the formation of the
hemostatic plug was also not affected (van Gestel et al., 2003).
There are various reasons as to why a genetic deletion may
lead to a different outcome than pharmacological inhibition in
growth and stability of the thrombus. An inhibitor can vary
in binding affinity for the receptor, reversibility, availability at
specific sites, and off-target effects, as compared to a complete
lack of receptor expression. Genetic deletion, on the other hand,
can lead to elimination not only of the gene of interest but
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can also alter levels of other genes that may be transcriptionally
regulated by the particular gene. Finally, since human and
murine platelets exhibit differences in content, the differences
in pharmacological inhibition vs. deletion can additionally be
related to species variability. Regardless, although an antagonist
may not completely inhibit the action of P2Y12 or account for
other functions of P2 receptors, it is clear that inhibition of
P2Y12 can be beneficial in limiting thrombus growth in arterial
thrombosis and secondary prevention of ischemia (Andre et al.,
2003; van Gestel et al., 2003).
PLATELETS AND P1 RECEPTORS
Adenosine Receptors in Platelets
In addition to P2 receptors, platelets express functional P1
purinergic receptors on their surfaces. As mentioned earlier,
P1 purinergic receptors are activated by adenosine at various
concentrations that may be generated by ATP/ADP hydrolysis.
In addition, an increase in levels of nucleotides, and consequent
adenosine generation, can occur during inflammation, cell
damage during infection, or other cardiovascular pathologies
(Fredholm, 2007; Koupenova and Ravid, 2013). Human and
murine platelets express functional cAMP-increasing P1
receptors A2aAR and A2bAR (Ledent et al., 1997; Yang et al.,
2010), but are not known to have functional cAMP-inhibiting
P1 receptors A1AR and A3AR. It is noteworthy that A1AR
mRNA has been detected by qRT-PCR (Amisten et al., 2008)
but significant expression was not detected by sequencing in
more recent studies (Rowley et al., 2011; Clancy et al., 2017). An
increased level of intracellular cAMP, in turn, inhibits platelet
aggregation/function.
Among the A2 adenosine receptors, A2aAR has the highest
affinity for adenosine and is the major adenosine receptor
expressed in platelets that mediates inhibition of platelet
aggregation. A2aAR is a G-protein-coupled receptor that couples
with Gαs and activates adenylyl cyclase (Koupenova et al.,
2012). A2aAR mediates platelet function through increasing
cAMP levels (Yang et al., 2010), and by inhibiting the rise
of thrombin-mediated increase in intracellular calcium levels
(Paul et al., 1990). Both of these effects on intracellular
second messengers in platelets are presumed to be mediated
by the action of adenylyl cyclase (Paul et al., 1990). It is
now understood that the inhibitory effect of cAMP on platelet
aggregation involves complex regulation of diverging signaling
pathways. Intracellularly, cAMP affects calcium signaling by
inhibiting PLC-mediated diacylglycerol (DAG) and inositol
triphosphate formation, by inhibiting protein kinase C directly
or indirectly through reduction of DAG level, or by affecting actin
polymerization through phosphorylation of the β-subunit of the
glycoprotein receptor GPIb (Fox and Berndt, 1989; Schwarz et al.,
2001; Varga-Szabo et al., 2009). In addition to inhibiting platelet
aggregation in human blood, activation of A2aAR by specific
agonists leads to a reduction in P-selectin expression on the
platelet cell surface, as a result of TxA2 or ADP stimulation. This
is followed by a greater than 50% reduction in platelet–monocyte
aggregate formation (Linden et al., 2008). This suggests that the
A2aAR has the potential to mediate the impact of prothrombotic
agonists during hemostasis and thrombosis as a fast responder.
Studies utilizing platelets from A2aAR null mice have
confirmed that inhibition of platelet aggregation is mediated
by this receptor, as platelets without A2aAR have an
increased aggregation potential and are not affected by
any concentration of the adenosine receptor (non-specific)
agonist, 5′-N-ethylcarboxamidoadenosine (NECA) (Ledent
et al., 1997). Similarly, inhibition of A2aAR by caffeine, a
non-specific adenosine receptor antagonist, also leads to
decreased aggregation potential of human platelets (Varani
et al., 1999, 2000). However, chronic intake of caffeine leads to
a desensitization effect on aggregation, possibly mediated by
increased upregulation of A2aAR (or A2bAR) on the platelet
surface (Varani et al., 1999, 2000).
Although platelets have a large density of A2aAR, they also
contain A2bARs. Similarly to A2aAR, A2bAR is a G-protein
receptor that couples to Gαs (Koupenova et al., 2012), but
can also couple to Gαq (Feoktistov et al., 1994; Linden et al.,
1999; Gao et al., 2017) and, in some cells, to Gαi (Gao
et al., 2017). Importantly, in different cells, A2bAR can couple
to the same pathways through different G-proteins possibly
depending on specific intracellular G-protein signatures (Gao
et al., 2017). In cells of the same type, A2bAR can also couple
to Gαs or Gαi leading to activation of opposing or synergistic
signaling pathways (Gao et al., 2017), suggesting that these
adenosine receptors have the ability to balance different signaling
mechanisms in different cell types. Contrary to the other P1
receptors, A2bAR is a low affinity receptor that requires the
concentration of adenosine to be higher than 10 µM (reviewed
in Koupenova and Ravid, 2013). Additionally, A2bAR is an
inducible receptor, the expression of which is known to be
upregulated under inflammation, stress, or vascular injury (Yang
et al., 2006, 2008, 2010; St. Hilaire et al., 2008). Since platelets are
anucleate cells, increase in A2bAR expression most likely occurs
in the platelet precursors, the megakaryocytes (MK). The low
affinity for adenosine, the inducibility of A2bAR expression, and
the promiscuous coupling with downstream G-proteins suggest
that this receptor may play an instrumental role in platelet
function during chronic inflammation and pathophysiological
conditions.
Recent sequencing studies show that mRNA expression of
A2bAR in human platelets is almost sixfold lower than A2aAR
(Table 1) (Rowley et al., 2011). Murine platelets lacking A2bAR
have reduced cAMP levels and are prone to increased ADP- or
collagen-mediated aggregation (Yang et al., 2010). Additionally,
A2bAR increases the inhibition of ADP-mediated aggregation of
platelets isolated from LPS-injected animals (Yang et al., 2010).
Elimination of A2bAR also leads to increased platelet expression
of the P2Y1 receptor (Yang et al., 2010), and P2Y1 activation, as
mentioned before, leads to an increase in intracellular calcium
levels (Cattaneo, 2007; Hechler and Gachet, 2011). This suggests
that the absence of A2bAR can have a stimulatory effect on
platelet aggregation through simultaneous reduction of cAMP
and increase in calcium levels. A2bAR signaling could be
particularly important over prolonged periods of inflammation
or injury.
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TABLE 1 | Platelet purinergic receptors assessed by RNA sequencing of healthy human or murine platelets.
Purinergic
receptor
Nucleotide/
nucleoside
G-Protein
coupling
Effect on
platelet
cAMP
Effect on
platelet
calcium
Large human
platelets
(Clancy et al.,
2017) (FPKM)
Small human
platelets
(Clancy et al.,
2017) (FPKM)
All human
platelets
(Rowley
et al., 2011)
(RPKM)
All murine
platelets
(Rowley
et al., 2011)
(RPKM)
P1 Purinergic receptors
A1AR Ado Gα i – – 0 0 0.05 0
A3AR Ado Gα i – – 0 1.80 0.08 1.86
A2aAR Ado Gαs ↑ – 0 2.23 31.80 0.36
A2bAR Ado Gαs ↑ – 0 0 5.37 0
P2 Purinergic receptors
P2X1 ATP Ion-gated
channel
– ↑ 4.21 1.55 90.79 630.06
P2Y1 ADP Gαq – ↑ 0 0 12.53 30.56
P2Y12 ADP Gα i ↓ – 13.19 1.77 73.75 1044.24
The two studies summarized here included healthy human donors and isolated platelets by sorting [large and small platelets (Clancy et al., 2017)] or by centrifugation
followed by leukocyte depletion (Rowley et al., 2011). The human cohorts, methods of platelet isolation, and RNA extractions are described in Rowley et al. (2011) and
Clancy et al. (2017). Mice sequencing data represent RNA transcripts in platelets from male and female C57BL/6 murine models (Rowley et al., 2011). Of note: The
data summarized here are derived from platelets from two human male donors (large and small platelets) and from one male and one female donor (data in “all platelet”
column). Data validation is required in various individuals of different ages and sexes in order to establish a broader distribution profile of purinergic receptors. cAMP,
cyclic AMP; FPKM, fragments per kilobase of transcript per million mapped reads; RPKM, reads per kilobase of transcript per million mapped reads; Ado, Adenosine;
ATP, adenosine triphosphate; ADP, adenosine diphosphate.
PURINERGIC RECEPTORS AND
PLATELET HETEROGENEITY
Circulating platelets are anucleate cell fragments originating from
their bone marrow precursor, the MK. Human platelets are
not a homogeneous population, but vary in size (2–5 µm) and
content. RNA sequencing shows that platelets may contain as
many as 9500 different transcripts (Rowley et al., 2011; Bray
et al., 2013; Clancy et al., 2017), most of which are prepackaged
from the MK. Additionally, platelets uptake transcripts and
transcript fragments from circulating cells and the endothelium
(Clancy et al., 2017). The heterogeneous size of platelets (Thon
and Italiano, 2012) is hypothesized to be a result of platelets
losing their contents into the circulation as they age; hence, large
platelets are also referred to as “immature” and small platelets
are referred to as “mature” (Penington and Streatfield, 1975;
Penington et al., 1976a,b). Alternatively, in the late 1970s, it was
proposed that platelets vary in density and structure depending
on ploidy of the MK from which platelets are originating. Low
ploidy MKs produce less hemostatically active platelets while
high ploidy MKs produce hemostatically functional platelets
(Penington and Streatfield, 1975; Penington et al., 1976a,b).
Direct experimental evidence is limited for each of these
hypotheses and it is possible that both of these explanations are
valid. Studies have shown that large (immature) platelets are
highly hemostatically active while small (mature) platelets are less
hemostatically functional (Thompson et al., 1984; Guthikonda
et al., 2008). It is noteworthy that the predominant size of platelets
in a healthy individual lies somewhere in between (Clancy et al.,
2017). In patients with acute coronary syndrome (developing
early stent thrombosis) there is a baseline platelet size increase
predicting platelet reactivity (Huczek et al., 2010). A population
study performed with patients after non-cardiac surgery has
provided evidence that large platelets may be a novel biomarker
for adverse cardiovascular events (Anetsberger et al., 2017).
Sequencing studies have addressed the overall platelet mRNA
transcriptome of the entire platelet population (Rowley et al.,
2011) and that of small and large platelets sorted from the
blood of healthy human donors (Clancy et al., 2017). Of
note, in platelets there is a reported mismatch between mRNA
and protein expression (Burkhart et al., 2012) that can be
partially justified by the ability of platelets to uptake mRNA
transcripts (Clancy et al., 2017). However, in cases when both
proteins and transcripts are detectable in platelets, there is
strong evidence that mRNA and the corresponding protein
expression are correlated (Rowley and Weyrich, 2013). Large
platelets (sorted as 10% of the entire platelet population) have
transcripts associated with classical platelet functions, such as
platelet activation/aggregation, hemostasis, and wound healing
(Clancy et al., 2017). Small platelets show a distinct and more
diverse platelet transcriptome as compared to large platelets,
and those transcripts are more involved in platelet-immune cell
interactions and apoptosis (Clancy et al., 2017). For instance,
small platelets contain distinct transcripts that are associated
with activation, proliferation and differentiation of T- and B-
lymphocytes (Clancy et al., 2017). Consistent with the hemostatic
role of large platelets and their contribution to aggregation,
transcripts for the P2 purinergic receptors, P2Y12 and P2X1,
seem to be present at higher levels in this platelet population
(Table 1). mRNA from the inhibitory P1 receptor A2aAR
is distinctly located in small platelets, similar to P1 A3AR
(Table 1). The function of platelet-A3AR is unclear. On the other
hand, sequencing of the entire platelet population, that includes
platelets of all sizes, shows the presence of all four P1 purinergic
receptors with the inhibitory A2aAR and A2bAR receptors in
the highest proportions (Table 1). Interestingly, P2Y1 is detected
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only in the mixed, non-sorted platelet population, but not in
the large or small platelet subpopulations. There is a possibility
that the P2Y1 receptor is present on platelets which compose
the rest of the platelet population that was not included in the
large/small platelet sorting, or P2Y1 was not detected due to low
expression levels in each group or in these particular donors.
The two sequencing studies also agree on transcripts for other
P2 purinergic receptors such as P2X5, P2Y10, and P2Y13 that
have not been previously reported to be present in platelets or to
have a functional role. Distinct signatures of purinergic receptors
in different platelet subpopulations suggests that the architecture
of the hemostatic plug may involve platelets of heterogeneous
size and function. Large platelets may be predominantly located
at the core while small platelets may be located (together with
the large) in the shell (Figure 1). Since small platelets have
more immune transcripts and are less hemostatically active,
their presence may allow for direct interactions with immune
cells inside of the shell of the thrombus. The mechanism
by which MKs mediate this diverse distribution of distinct
transcripts in platelets according to size and function is still
controversial.
CONCLUSION AND FUTURE
DIRECTIONS
The distinct distribution of purinergic receptor types across
different platelet sizes may provide a new approach to
FIGURE 1 | Distribution of purinergic receptor transcripts with known function in the entire platelet population vs. large and small platelets. Platelets are a
heterogeneous population of various sizes. Large platelets are highly hemostatically active while small ones are known to be much less active in hemostasis
(Thompson et al., 1984; Guthikonda et al., 2008). RNA sequencing studies shown in Table 1 suggest differential distribution of purinergic receptors across platelets
of different sizes, providing a provocative hypothesis related to potential functional differences in hemostasis when activated by adenine nucleosides and nucleotides,
depending on platelet size. Future protein studies will be needed to test this contention. P2X1 is a ligand-gated ion channel that requires binding of ATP for influx of
calcium; the rest of the P2 and P1 receptors in platelets are G-protein-coupled receptors. Of note, with the sensitivity of the above method of detection, P2Y1 or
A2bAR transcripts are not found in the small or large platelets; however, these receptors for ADP or adenosine (respectively) are detected in the entire platelet
population, suggesting a differential expression level in different platelet populations, possibly necessary for an extra layer of control over platelet function. These
findings further encourage future examination of the receptors at protein and functional levels in different platelet populations. It is not known, however, if all of the
purinergic receptors depicted in the top (or bottom) panel can be expressed on the same platelet, if there is differential signature of co-expression or if there is a mix
of both of these possibilities. Ado, adenosine; ATP, adenosine triphosphate; ADP, adenosine diphosphate; cAMP, cyclic adenosine monophosphate; AC, adenylate
cyclase.
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purinergic signaling manipulation in order to establish effective
antithrombotic therapies. The platelet mRNA profile may have
a broader impact on overall platelet function, and proposes
an explanation of previously identified functional differences
between small and large platelets, with increased mean platelet
volume being historically associated with increased hemostatic
potential. It remains unclear, however, if within the sophisticated
architecture of the thrombus there is a distinct arrangement of
platelets with differential expression of purinergic or immune
receptors. Perhaps, big platelets are primarily responsible for
the formation of the core of the hemostatic plug since they
predominantly contain transcripts related to the hemostatic
function of platelets, such as the P2 receptors. Small platelets
in turn contain more immune transcripts. These cells may
need to communicate with both aggregated platelets and
leukocytes and may be located in the porous shell of the
hemostatic plaque. In that sense, it would be necessary for
small platelets to be less prone to aggregation and hence
express only purinergic receptors for shape change (P2X1) and
reduction of aggregation (A2ARs). It is also not completely
clear if platelet heterogeneity increases as a function of
pathological conditions, thereby changing the balance between
P2/P1 receptors and limiting the beneficial effect of current
therapies.
It would be important to test these receptors at protein and
agonist functional levels in the different platelet subpopulations.
Additionally, future studies are necessary to elucidate the
complex cross-communication of purinergic receptors in the
hemostatic plug as a function of platelet heterogeneity and
to determine if there is a functional presence of the other
ADP/ATP receptors that were detected at mRNA level. These
future findings may provide additional pharmacological targets
in the management of thrombus growth and stability in patients.
AUTHOR CONTRIBUTIONS
MK and KR co-wrote and edited this review article.
FUNDING
This work was supported by AHA Award 16SDG30450001 (to
MK) and the Thrombosis and Hemostasis Affinity Research
Collaborative and the Evans Center for Interdisciplinary
Biomedical Research at Boston University School of Medicine
(to KR). KR is an Established Investigator with the American
Heart Association.
ACKNOWLEDGMENTS
We apologize to all whose work was not cited due to limited
space.
REFERENCES
Amisten, S., Braun, O. O., Bengtsson, A., and Erlinge, D. (2008). Gene expression
profiling for the identification of G-protein coupled receptors in human
platelets. Thromb. Res. 122, 47–57.
Andre, P., Delaney, S. M., Larocca, T., Vincent, D., Deguzman, F., Jurek, M., et al.
(2003). P2Y12 regulates platelet adhesion/activation, thrombus growth, and
thrombus stability in injured arteries. J. Clin. Invest. 112, 398–406.
Anetsberger, A., Blobner, M., Haller, B., Schmid, S., Umgelter, K., Hager, T., et al.
(2017). Immature platelets as a novel biomarker for adverse cardiovascular
events in patients after non-cardiac surgery. Thromb. Haemost. 117, 1887–1895.
doi: 10.1160/TH16-10-0804
Bray, P. F., Mckenzie, S. E., Edelstein, L. C., Nagalla, S., Delgrosso, K., Ertel, A., et al.
(2013). The complex transcriptional landscape of the anucleate human platelet.
BMC Genomics 14:1. doi: 10.1186/1471-2164-14-1
Burkhart, J. M., Vaudel, M., Gambaryan, S., Radau, S., Walter, U., Martens, L.,
et al. (2012). The first comprehensive and quantitative analysis of human
platelet protein composition allows the comparative analysis of structural and
functional pathways. Blood 120, e73–82. doi: 10.1182/blood-2012-04-416594
Castilhos, L. G., Doleski, P. H., Adefegha, S. A., Becker, L. V., Ruchel, J. B., and
Leal, D. B. (2016). Altered E-NTPDase/E-ADA activities and CD39 expression
in platelets of sickle cell anemia patients. Biomed. Pharmacother. 79, 241–246.
doi: 10.1016/j.biopha.2016.02.009
Cattaneo, M. (2007). Platelet P2 receptors: old and new targets for antithrombotic
drugs. Expert Rev. Cardiovasc. Ther. 5, 45–55.
Cattaneo, M., Lecchi, A., Lombardi, R., Gachet, C., and Zighetti, M. L. (2000).
Platelets from a patient heterozygous for the defect of P2CYC receptors for ADP
have a secretion defect despite normal thromboxane A2 production and normal
granule stores: further evidence that some cases of platelet ’primary secretion
defect’ are heterozygous for a defect of P2CYC receptors. Arterioscler. Thromb.
Vasc. Biol. 20, E101–E106.
Cattaneo, M., Lecchi, A., Randi, A. M., Mcgregor, J. L., and Mannucci, P. M. (1992).
Identification of a new congenital defect of platelet function characterized by
severe impairment of platelet responses to adenosine diphosphate. Blood 80,
2787–2796.
Clancy, L., Beaulieu, L. M., Tanriverdi, K., and Freedman, J. E. (2017). The role
of RNA uptake in platelet heterogeneity. Thromb. Haemost. 117, 948–961.
doi: 10.1160/TH16-11-0873
Dorsam, R. T., and Kunapuli, S. P. (2004). Central role of the P2Y12 receptor in
platelet activation. J. Clin. Invest. 113, 340–345.
Erhardt, J. A., Toomey, J. R., Douglas, S. A., and Johns, D. G. (2006).
P2X1 stimulation promotes thrombin receptor-mediated platelet aggregation.
J. Thromb. Haemost. 4, 882–890.
Fabre, J. E., Nguyen, M., Latour, A., Keifer, J. A., Audoly, L. P., Coffman, T. M., et al.
(1999). Decreased platelet aggregation, increased bleeding time and resistance
to thromboembolism in P2Y1-deficient mice. Nat. Med. 5, 1199–1202.
Feoktistov, I., Murray, J. J., and Biaggioni, I. (1994). Positive modulation
of intracellular Ca2+ levels by adenosine A2b receptors, prostacyclin,
and prostaglandin E1 via a cholera toxin-sensitive mechanism in human
erythroleukemia cells. Mol. Pharmacol. 45, 1160–1167.
Fox, J. E., and Berndt, M. C. (1989). Cyclic AMP-dependent phosphorylation of
glycoprotein Ib inhibits collagen-induced polymerization of actin in platelets.
J. Biol. Chem. 264, 9520–9526.
Fredholm, B. B. (2007). Adenosine, an endogenous distress signal, modulates tissue
damage and repair. Cell Death Differ. 14, 1315–1323.
Fung, C. Y., Jones, S., Ntrakwah, A., Naseem, K. M., Farndale, R. W., and
Mahaut-Smith, M. P. (2012). Platelet Ca(2+) responses coupled to glycoprotein
VI and Toll-like receptors persist in the presence of endothelial-derived
inhibitors: roles for secondary activation of P2X1 receptors and release from
intracellular Ca(2+) stores. Blood 119, 3613–3621. doi: 10.1182/blood-2011-10-
386052
Gao, Z. G., Inoue, A., and Jacobson, K. A. (2017). On the G protein-
coupling selectivity of the native A2B adenosine receptor. Biochem. Pharmacol.
doi: 10.1016/j.bcp.2017.12.003 [Epub ahead of print].
Guthikonda, S., Alviar, C. L., Vaduganathan, M., Arikan, M., Tellez, A., Delao, T.,
et al. (2008). Role of reticulated platelets and platelet size heterogeneity on
Frontiers in Pharmacology | www.frontiersin.org 7 January 2018 | Volume 9 | Article 37
fphar-09-00037 January 27, 2018 Time: 15:15 # 8
Koupenova and Ravid Platelet Purinergic Receptors and Their Heterogeneity
platelet activity after dual antiplatelet therapy with aspirin and clopidogrel in
patients with stable coronary artery disease. J. Am. Coll. Cardiol. 52, 743–749.
doi: 10.1016/j.jacc.2008.05.031
Hardy, A. R., Jones, M. L., Mundell, S. J., and Poole, A. W. (2004). Reciprocal
cross-talk between P2Y1 and P2Y12 receptors at the level of calcium signaling
in human platelets. Blood 104, 1745–1752.
Hechler, B., and Gachet, C. (2011). P2 receptors and platelet function. Purinergic
Signal. 7, 293–303. doi: 10.1007/s11302-011-9247-6
Hechler, B., Lenain, N., Marchese, P., Vial, C., Heim, V., Freund, M., et al. (2003a).
A role of the fast ATP-gated P2X1 cation channel in thrombosis of small arteries
in vivo. J. Exp. Med. 198, 661–667.
Hechler, B., Zhang, Y., Eckly, A., Cazenave, J. P., Gachet, C., and Ravid, K.
(2003b). Lineage-specific overexpression of the P2Y1 receptor induces platelet
hyper-reactivity in transgenic mice. J. Thromb. Haemost. 1, 155–163.
Hollopeter, G., Jantzen, H. M., Vincent, D., Li, G., England, L., Ramakrishnan, V.,
et al. (2001). Identification of the platelet ADP receptor targeted by
antithrombotic drugs. Nature 409, 202–207.
Huang, Z., Liu, P., Zhu, L., Li, N., and Hu, H. (2014). P2X1-initiated
p38 signalling enhances thromboxane A2-induced platelet secretion and
aggregation. Thromb. Haemost. 112, 142–150. doi: 10.1160/TH13-09-0726
Huczek, Z., Filipiak, K. J., Kochman, J., Michalak, M., Roik, M., Piatkowski, R.,
et al. (2010). Baseline platelet size is increased in patients with acute coronary
syndromes developing early stent thrombosis and predicts future residual
platelet reactivity. A case-control study. Thromb. Res. 125, 406–412. doi: 10.
1016/j.thromres.2009.09.003
Jacobson, K. A., Costanzi, S., Joshi, B. V., Besada, P., Shin, D. H., Ko, H., et al.
(2006). Agonists and antagonists for P2 receptors. Novartis Found. Symp. 276,
58–281.
Jin, J., Quinton, T. M., Zhang, J., Rittenhouse, S. E., and Kunapuli, S. P. (2002).
Adenosine diphosphate (ADP)-induced thromboxane A(2) generation
in human platelets requires coordinated signaling through integrin
alpha(IIb)beta(3) and ADP receptors. Blood 99, 193–198.
Jones, S., Evans, R. J., and Mahaut-Smith, M. P. (2014). Ca2+ influx through P2X1
receptors amplifies P2Y1 receptor-evoked Ca2+ signaling and ADP-evoked
platelet aggregation. Mol. Pharmacol. 86, 243–251. doi: 10.1124/mol.114.092528
Kaplan, Z. S., Zarpellon, A., Alwis, I., Yuan, Y., Mcfadyen, J., Ghasemzadeh, M.,
et al. (2015). Thrombin-dependent intravascular leukocyte trafficking regulated
by fibrin and the platelet receptors GPIb and PAR4. Nat. Commun. 6:7835.
doi: 10.1038/ncomms8835
Koupenova, M., Johnston-Cox, H., and Ravid, K. (2012). Regulation of
atherosclerosis and associated risk factors by adenosine and adenosine
receptors. Curr. Atheroscler. Rep. 14, 460–468. doi: 10.1007/s11883-012-0263-y
Koupenova, M., Kehrel, B. E., Corkrey, H. A., and Freedman, J. E. (2017).
Thrombosis and platelets: an update. Eur. Heart J. 38, 785–791. doi: 10.1093/
eurheartj/ehw550
Koupenova, M., and Ravid, K. (2013). Adenosine, adenosine receptors and their
role in glucose homeostasis and lipid metabolism. J. Cell Physiol. doi: 10.1002/
jcp.24352 [Epub ahead of print].
Koziak, K., Sevigny, J., Robson, S. C., Siegel, J. B., and Kaczmarek, E.
(1999). Analysis of CD39/ATP diphosphohydrolase (ATPDase) expression in
endothelial cells, platelets and leukocytes. Thromb. Haemost. 82, 1538–1544.
Larson, M. K., Chen, H., Kahn, M. L., Taylor, A. M., Fabre, J. E., Mortensen, R. M.,
et al. (2003). Identification of P2Y12-dependent and -independent mechanisms
of glycoprotein VI-mediated Rap1 activation in platelets. Blood 101, 1409–1415.
Ledent, C., Vaugeois, J. M., Schiffmann, S. N., Pedrazzini, T., El Yacoubi, M.,
Vanderhaeghen, J. J., et al. (1997). Aggressiveness, hypoalgesia and high blood
pressure in mice lacking the adenosine A2a receptor. Nature 388, 674–678.
Leon, C., Hechler, B., Freund, M., Eckly, A., Vial, C., Ohlmann, P., et al.
(1999). Defective platelet aggregation and increased resistance to thrombosis
in purinergic P2Y(1) receptor-null mice. J. Clin. Invest. 104, 1731–1737.
Linden, J., Thai, T., Figler, H., Jin, X., and Robeva, A. S. (1999). Characterization of
human A(2B) adenosine receptors: radioligand binding, western blotting, and
coupling to G(q) in human embryonic kidney 293 cells and HMC-1 mast cells.
Mol. Pharmacol. 56, 705–713.
Linden, M. D., Barnard, M. R., Frelinger, A. L., Michelson, A. D., and Przyklenk, K.
(2008). Effect of adenosine A2 receptor stimulation on platelet activation-
aggregation: differences between canine and human models. Thromb. Res. 121,
689–698.
Mahaut-Smith, M. P. (2012). The unique contribution of ion channels to platelet
and megakaryocyte function. J. Thromb. Haemost. 10, 1722–1732. doi: 10.1111/
j.1538-7836.2012.04837.x
McNicol, A., and Israels, S. J. (1999). Platelet dense granules: structure, function
and implications for haemostasis. Thromb. Res. 95, 1–18.
Oury, C., Sticker, E., Cornelissen, H., De Vos, R., Vermylen, J., and Hoylaerts,
M. F. (2004). ATP augments von Willebrand factor-dependent shear-induced
platelet aggregation through Ca2+-calmodulin and myosin light chain kinase
activation. J. Biol. Chem. 279, 26266–26273.
Oury, C., Toth-Zsamboki, E., Thys, C., Tytgat, J., Vermylen, J., and Hoylaerts, M. F.
(2001). The ATP-gated P2X1 ion channel acts as a positive regulator of platelet
responses to collagen. Thromb. Haemost. 86, 1264–1271.
Paul, S., Feoktistov, I., Hollister, A. S., Robertson, D., and Biaggioni, I. (1990).
Adenosine inhibits the rise in intracellular calcium and platelet aggregation
produced by thrombin: evidence that both effects are coupled to adenylate
cyclase. Mol. Pharmacol. 37, 870–875.
Penington, D. G., Lee, N. L., Roxburgh, A. E., and Mcgready, J. R. (1976a).
Platelet density and size: the interpretation of heterogeneity. Br. J. Haematol.
34, 365–376.
Penington, D. G., and Streatfield, K. (1975). Heterogeneity of megakaryocytes and
platelets. Ser. Haematol. 8, 22–48.
Penington, D. G., Streatfield, K., and Roxburgh, A. E. (1976b). Megakaryocytes
and the heterogeneity of circulating platelets. Br. J. Haematol. 34,
639–653.
Quinton, T. M., and Dean, W. L. (1992). Cyclic AMP-dependent phosphorylation
of the inositol-1,4,5-trisphosphate receptor inhibits Ca2+ release
from platelet membranes. Biochem. Biophys. Res. Commun. 184,
893–899.
Rolf, M. G., Brearley, C. A., and Mahaut-Smith, M. P. (2001). Platelet shape
change evoked by selective activation of P2X1 purinoceptors with alpha,beta-
methylene ATP. Thromb. Haemost. 85, 303–308.
Rowley, J. W., Oler, A. J., Tolley, N. D., Hunter, B. N., Low, E. N., Nix,
D. A., et al. (2011). Genome-wide RNA-seq analysis of human and mouse
platelet transcriptomes. Blood 118, e101–e111. doi: 10.1182/blood-2011-03-
339705
Rowley, J. W., and Weyrich, A. S. (2013). Coordinate expression of transcripts and
proteins in platelets. Blood 121, 5255–5256.
Schwarz, U. R., Walter, U., and Eigenthaler, M. (2001). Taming platelets with cyclic
nucleotides. Biochem. Pharmacol. 62, 1153–1161.
Shankar, H., Murugappan, S., Kim, S., Jin, J., Ding, Z., Wickman, K., et al.
(2004). Role of G protein-gated inwardly rectifying potassium channels
in P2Y12 receptor-mediated platelet functional responses. Blood 104,
1335–1343.
St. Hilaire, C., Koupenova, M., Carroll, S. H., Smith, B. D., and Ravid, K. (2008).
TNF-alpha upregulates the A2B adenosine receptor gene: The role of NAD(P)H
oxidase 4. Biochem. Biophys. Res. Commun. 375, 292–296. doi: 10.1016/j.bbrc.
2008.07.059
Stalker, T. J., Traxler, E. A., Wu, J., Wannemacher, K. M., Cermignano, S. L.,
Voronov, R., et al. (2013). Hierarchical organization in the hemostatic response
and its relationship to the platelet-signaling network. Blood 121, 1875–1885.
doi: 10.1182/blood-2012-09-457739
Stefanini, L., and Bergmeier, W. (2017). Negative regulators of platelet activation
and adhesion. J. Thromb. Haemost. doi: 10.1111/jth.13910 [Epub ahead of
print].
Stolla, M., Stefanini, L., Andre, P., Ouellette, T. D., Reilly, M. P., Mckenzie,
S. E., et al. (2011a). CalDAG-GEFI deficiency protects mice in a novel model
of Fcgamma RIIA-mediated thrombosis and thrombocytopenia. Blood 118,
1113–1120. doi: 10.1182/blood-2011-03-342352
Stolla, M., Stefanini, L., Roden, R. C., Chavez, M., Hirsch, J., Greene, T., et al.
(2011b). The kinetics of alphaIIbbeta3 activation determines the size and
stability of thrombi in mice: implications for antiplatelet therapy. Blood 117,
1005–1013. doi: 10.1182/blood-2010-07-297713
Sun, B., Li, J., Okahara, K., and Kambayashi, J. (1998). P2X1 purinoceptor
in human platelets. Molecular cloning and functional characterization after
heterologous expression. J. Biol. Chem. 273, 11544–11547.
Tertyshnikova, S., and Fein, A. (1998). Inhibition of inositol 1,4,5-trisphosphate-
induced Ca2+ release by cAMP-dependent protein kinase in a living cell. Proc.
Natl. Acad. Sci. U.S.A. 95, 1613–1617.
Frontiers in Pharmacology | www.frontiersin.org 8 January 2018 | Volume 9 | Article 37
fphar-09-00037 January 27, 2018 Time: 15:15 # 9
Koupenova and Ravid Platelet Purinergic Receptors and Their Heterogeneity
Thompson, C. B., Jakubowski, J. A., Quinn, P. G., Deykin, D., and Valeri, C. R.
(1984). Platelet size and age determine platelet function independently. Blood
63, 1372–1375.
Thon, J. N., and Italiano, J. E. Jr. (2012). Does size matter in platelet production?
Blood 120, 1552–1561. doi: 10.1182/blood-2012-04-408724
Tomaiuolo, M., Brass, L. F., and Stalker, T. J. (2017). Regulation of
platelet activation and coagulation and its role in vascular injury and
arterial thrombosis. Interv. Cardiol. Clin. 6, 1–12. doi: 10.1016/j.iccl.2016.
08.001
Toth-Zsamboki, E., Oury, C., Cornelissen, H., De Vos, R., Vermylen, J., and
Hoylaerts, M. F. (2003). P2X1-mediated ERK2 activation amplifies the collagen-
induced platelet secretion by enhancing myosin light chain kinase activation.
J. Biol. Chem. 278, 46661–46667.
van Gestel, M. A., Heemskerk, J. W., Slaaf, D. W., Heijnen, V. V., Reneman, R. S.,
and Oude Egbrink, M. G. (2003). In vivo blockade of platelet ADP receptor
P2Y12 reduces embolus and thrombus formation but not thrombus stability.
Arterioscler. Thromb. Vasc. Biol. 23, 518–523.
Varani, K., Portaluppi, F., Gessi, S., Merighi, S., Ongini, E., Belardinelli, L., et al.
(2000). Dose and time effects of caffeine intake on human platelet adenosine
A(2A) receptors : functional and biochemical aspects. Circulation 102,
285–289.
Varani, K., Portaluppi, F., Merighi, S., Ongini, E., Belardinelli, L., and Borea, P. A.
(1999). Caffeine alters A2A adenosine receptors and their function in human
platelets. Circulation 99, 2499–2502.
Varga-Szabo, D., Braun, A., and Nieswandt, B. (2009). Calcium signaling in
platelets. J. Thromb. Haemost. 7, 1057–1066. doi: 10.1111/j.1538-7836.2009.
03455.x
Yang, D., Chen, H., Koupenova, M., Carroll, S. H., Eliades, A., Freedman, J. E.,
et al. (2010). A new role for the A2b adenosine receptor in regulating platelet
function. J. Thromb. Haemost. 8, 817–827. doi: 10.1111/j.1538-7836.2010.
03769.x
Yang, D., Koupenova, M., Mccrann, D. J., Kopeikina, K. J., Kagan, H. M., Schreiber,
B. M., et al. (2008). The A2b adenosine receptor protects against vascular injury.
Proc. Natl. Acad. Sci. U.S.A. 105, 792–796. doi: 10.1073/pnas.0705563105
Yang, D., Zhang, Y., Nguyen, H. G., Koupenova, M., Chauhan, A. K., Makitalo, M.,
et al. (2006). The A2B adenosine receptor protects against inflammation and
excessive vascular adhesion. J. Clin. Invest. 116, 1913–1923.
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2018 Koupenova and Ravid. This is an open-access article distributed
under the terms of the Creative Commons Attribution License (CC BY). The use,
distribution or reproduction in other forums is permitted, provided the original
author(s) and the copyright owner are credited and that the original publication
in this journal is cited, in accordance with accepted academic practice. No use,
distribution or reproduction is permitted which does not comply with these terms.
Frontiers in Pharmacology | www.frontiersin.org 9 January 2018 | Volume 9 | Article 37
